TAILORing targeted therapies to the right patient at the right time: how close are we?

George Zarkavelis, George Pentheroudakis


The therapeutic landscape of metastatic colorectal cancer has dramatically evolved over the last decade leading to improved survival outcomes. Patients can now achieve median survival times in excess of 2 years with the use of targeted therapies that have become an integral part of colon cancer therapeutics (1).